Imugene (ASX:IMU) received a notice of allowance from the US Patent and Trademark Office for patent application number 16/637,909, protecting its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR T cell therapies, according to a Wednesday filing with the Australian bourse.
The patent offers protection for the method of composition and method of use through to Aug. 10, 2038, the filing said.
Shares fell past 7% in midday trade Wednesday and hit their lowest since January 2018.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。